ATE292801T1 - Verfahren zum screening von inhibitoren von asp2 - Google Patents

Verfahren zum screening von inhibitoren von asp2

Info

Publication number
ATE292801T1
ATE292801T1 AT00969693T AT00969693T ATE292801T1 AT E292801 T1 ATE292801 T1 AT E292801T1 AT 00969693 T AT00969693 T AT 00969693T AT 00969693 T AT00969693 T AT 00969693T AT E292801 T1 ATE292801 T1 AT E292801T1
Authority
AT
Austria
Prior art keywords
cleavage
asp
compounds
substrate
asp2
Prior art date
Application number
AT00969693T
Other languages
English (en)
Inventor
Gary Christie
Ishrut Hussain
David Powell
Original Assignee
Smithkline Beecham Plc
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc, Smithkline Beecham Corp filed Critical Smithkline Beecham Plc
Application granted granted Critical
Publication of ATE292801T1 publication Critical patent/ATE292801T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711Alzheimer's disease; Amyloid plaque core protein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02Linear peptides containing at least one abnormal peptide link
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4709Amyloid plaque core protein
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/914Hydrolases (3)
    • G01N2333/948Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96472Aspartic endopeptidases (3.4.23)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/02Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Psychology (AREA)
AT00969693T 1999-10-21 2000-10-19 Verfahren zum screening von inhibitoren von asp2 ATE292801T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9924957.5A GB9924957D0 (en) 1999-10-21 1999-10-21 Novel treatment
PCT/GB2000/004039 WO2001029563A1 (en) 1999-10-21 2000-10-19 Method of screening for inhibitors of asp2

Publications (1)

Publication Number Publication Date
ATE292801T1 true ATE292801T1 (de) 2005-04-15

Family

ID=10863153

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00969693T ATE292801T1 (de) 1999-10-21 2000-10-19 Verfahren zum screening von inhibitoren von asp2

Country Status (9)

Country Link
US (2) US20050277165A1 (de)
EP (1) EP1224469B1 (de)
JP (1) JP2003512043A (de)
AT (1) ATE292801T1 (de)
AU (1) AU7934900A (de)
DE (1) DE60019321T2 (de)
ES (1) ES2240183T3 (de)
GB (1) GB9924957D0 (de)
WO (1) WO2001029563A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9701684D0 (en) 1997-01-28 1997-03-19 Smithkline Beecham Plc Novel compounds
US6699671B1 (en) 1998-09-24 2004-03-02 Pharmacia & Upjohn Company Alzheimer's disease secretase, APP substrates therefor, and uses therefor
KR20070013361A (ko) 1998-09-24 2007-01-30 파마시아 앤드 업존 캄파니 엘엘씨 알츠하이머병 세크레타제
US6844148B1 (en) 1998-09-24 2005-01-18 Pharmacia & Upjohn Company Alzheimer's disease secretase, APP substrates therefor, and uses therefor
US7115410B1 (en) 1999-02-10 2006-10-03 Elan Pharmaceuticals, Inc. β-secretase enzyme compositions and methods
US7456007B1 (en) 1998-12-31 2008-11-25 Elan Pharmaceuticals, Inc. β-secretase enzyme compositions and methods
JP4653318B2 (ja) 1999-02-10 2011-03-16 エラン ファーマシューティカルズ,インコーポレイテッド βセクレターゼ酵素組成物および方法
US7514408B1 (en) 1999-12-02 2009-04-07 Elan Pharmaceuticals, Inc. β-secretase enzyme compositions and methods
JP2003528071A (ja) 2000-03-23 2003-09-24 エラン ファーマスーティカルズ インコーポレイテッド アルツハイマー病治療用組成物および方法
JP2004502665A (ja) 2000-06-30 2004-01-29 イーラン ファーマスーティカルズ、インコーポレイテッド アルツハイマー病を治療する化合物
US6846813B2 (en) 2000-06-30 2005-01-25 Pharmacia & Upjohn Company Compounds to treat alzheimer's disease
PE20020276A1 (es) 2000-06-30 2002-04-06 Elan Pharm Inc COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
WO2003002122A1 (en) 2001-06-27 2003-01-09 Elan Pharmaceuticals, Inc. Beta-hydroxyamine derivatives useful in treatment of alzheimer's disease
CA2464736A1 (en) * 2001-10-23 2003-05-15 Oklahoma Medical Research Foundation Beta-secretase inhibitors and methods of use
TW200815349A (en) 2006-06-22 2008-04-01 Astrazeneca Ab New compounds
TW201020244A (en) 2008-11-14 2010-06-01 Astrazeneca Ab New compounds
EP2281824A1 (de) 2009-08-07 2011-02-09 Noscira, S.A. Furan-Imidazolon-Derivate zur Behandlung von kognitiven, neurodegenerativen oder neuronalen Erkrankungen oder Funktionsstörungen
TW201300417A (zh) 2010-11-10 2013-01-01 Genentech Inc 用於神經疾病免疫療法之方法及組合物
JP2013542973A (ja) 2010-11-22 2013-11-28 ノスシラ、ソシエダッド、アノニマ 神経変性疾患または神経変性状態を治療するためのビピリジンスルホンアミド誘導体
JP2013158281A (ja) * 2012-02-03 2013-08-19 Shionogi & Co Ltd 新規bace1活性測定方法
JP6612742B2 (ja) * 2013-06-12 2019-11-27 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 関節症の処置のためのヒドロキシエチレン誘導体
CN107108745B (zh) 2014-11-19 2021-01-12 基因泰克公司 抗bace1的抗体和其用于神经疾病免疫疗法的用途
WO2016081640A1 (en) 2014-11-19 2016-05-26 Genentech, Inc. Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5187153A (en) * 1986-11-17 1993-02-16 Scios Nova Inc. Methods of treatment using Alzheimer's amyloid polypeptide derivatives
US4963654A (en) * 1989-02-13 1990-10-16 Taisho Pharmaceutical Co., Ltd. Peptide serine protease inhibitor
US5292652A (en) * 1990-10-05 1994-03-08 Athena Neurosciences, Inc. Amyloidin protease and uses thereof
WO1995013084A1 (en) * 1992-05-11 1995-05-18 Miles Inc. Cathepsin d is an amyloidogenic protease in alzheimer's disease
AU6383396A (en) * 1995-06-07 1996-12-30 Athena Neurosciences, Inc. Beta-secretase, antibodies to beta-secretase, and assays for detecting beta-secretase inhibition
WO1998015828A1 (en) * 1996-10-07 1998-04-16 Scios Inc. Method to identify direct inhibitors of the beta-amyloid forming enzyme gamma-secretase
GB9701684D0 (en) * 1997-01-28 1997-03-19 Smithkline Beecham Plc Novel compounds
US6699671B1 (en) * 1998-09-24 2004-03-02 Pharmacia & Upjohn Company Alzheimer's disease secretase, APP substrates therefor, and uses therefor
US6313268B1 (en) * 1998-10-16 2001-11-06 Vivian Y. H. Hook Secretases related to Alzheimer's dementia
CA2374346C (en) * 1999-06-28 2010-06-22 Jordan J. N. Tang Inhibitors of memapsin 2 and use thereof

Also Published As

Publication number Publication date
ES2240183T3 (es) 2005-10-16
DE60019321T2 (de) 2005-09-08
US20070021348A1 (en) 2007-01-25
US20050277165A1 (en) 2005-12-15
AU7934900A (en) 2001-04-30
EP1224469A1 (de) 2002-07-24
GB9924957D0 (en) 1999-12-22
DE60019321D1 (de) 2005-05-12
JP2003512043A (ja) 2003-04-02
EP1224469B1 (de) 2005-04-06
WO2001029563A1 (en) 2001-04-26

Similar Documents

Publication Publication Date Title
DE60019321D1 (de) Verfahren zum screening von inhibitoren von asp2
ATE224713T1 (de) Verwendung von pyridyl-alkan-,pyridiyl alkan- und/oder pyridyl-säuren amiden zur behandlung von tumoren oder für immunsuppression
NO20052928L (no) Nye kjemiske forbindelser
DE69815090D1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
ATE279181T1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
NO20061736L (no) Krystallform av epotilon B
DE69528475D1 (de) Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
DE59611411D1 (de) Verwendung von alpha 1l-agonisten zur behandlung der harninkontinenz
DE69839815D1 (de) Verwendung von ppar-gamma aktivatoren zur behandlung von hautkrankheiten
DE60032795D1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
DE69918972D1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
ATE173620T1 (de) Verwendung eines antagonisten von tnf-alpha zur behandlung von hautrötungen neurogenen ursprungs
DK1234025T3 (da) Humane enzymer fra metalloproteasefamilien
DE69433243D1 (de) Verwendunf von ApoE zum Binden von TAU und MAP2c Proteinen und zur Behandlung von Alzheimer's Krankheit
DE60018200D1 (de) Verwendung von pleuromutilinderivaten zur transdermalen behandlung bakterieller erkrankungen
ATE283703T1 (de) Neurodegenerative-erkrankung verwandtes gen
ATE225171T1 (de) Aminosäurederivate zur behandlung von schlaganfall
DE60026644D1 (de) Verwendung von Ferulasäure zur Behandlung von Bluthochdruck
ATE423129T1 (de) Inhibitoren von lyn-verbundener signaltransduktion (last) und deren verwendung zur behandlung von prostatakrebs
DE60144493D1 (de) Verfahren zur bestimmung und behandlung von tuberöse-sklerose komplex assoziierten erkrankungen
DE69930844D1 (de) Inhibitoren von mycobakterien
DE60010934D1 (de) Medikamente geeignet zur Behandlung von proliferativen Erkrankungen
ATE320255T1 (de) Tie2 rezeptor-kinase-inhibitoren zur behandlung von angiogenen erkrankungen
DE60119671D1 (de) Verfahren zur Behandlung von Holzwerkstoff
EP1102599A4 (de) Protease hemmstoffe zur verwendung in der behandlung von psoriasis

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties